BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32720820)

  • 21. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
    Holdsworth MT; Nguyen P
    Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rasburicase (Fasturtec)].
    Vogt B; Gugger M; Frey FJ
    Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rasburicase for acute kidney injury.
    Sinha R; Dugar P
    Indian Pediatr; 2013 Nov; 50(11):1051-2. PubMed ID: 24382901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The pathophysiology, clinical signs and therapy of urate nephropathy].
    Méhes L; Udvardy M; Szász R; Rejto L
    Orv Hetil; 2007 Apr; 148(16):745-8. PubMed ID: 17437951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of single-dose rasburicase in an obese female.
    Arnold TM; Reuter JP; Delman BS; Shanholtz CB
    Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
    Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
    Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of impending tumor lysis with single-dose rasburicase.
    Lee AC; Li CH; So KT; Chan R
    Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
    Teo WY; Loh TF; Tan AM
    Ann Acad Med Singap; 2007 Aug; 36(8):679-83. PubMed ID: 17767339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of pediatric tumor lysis syndrome.
    Tazi I; Nafl H; Elhoudzi J; Mahmal L; Harif M
    Arab J Nephrol Transplant; 2011 Sep; 4(3):147-54. PubMed ID: 22026339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fast remission of acute kidney failure after rasburicase use in tumor lysis syndrome].
    Viedma G; Borrego FJ; Pérez del Barrio P; de Santi C
    Nefrologia; 2005; 25(5):572-3. PubMed ID: 16392310
    [No Abstract]   [Full Text] [Related]  

  • 35. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
    Ribeiro RC; Pui CH
    Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
    Jeha S; Pui CH
    Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Lysis Syndrome.
    Barbar T; Jaffer Sathick I
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor lysis syndrome, case report and review of the literature.
    Masera G; Jankovic M
    Ann Oncol; 1997 Jan; 8(1):97. PubMed ID: 9093714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.